fbpx

List – 107 Drug Patents that are Expiring between 2023 to 2025

Last year, we published an article covering 56 drug patents expiring between 2020-22. 2021 is already here and if you are working in the pharma domain, working on the development of generics, you would want to know what drug patents are expiring in the coming years, so you could plan accordingly. 

With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible, and keeping that very thought in mind, we collated a list of 107 drugs that are going off-patent from 2023 to 2025. We also included other information like yearly sales, dosage information, ingredients, and the diseases they cure. This could help you easily choose a drug most profitable to develop a generic version. 

Loved the idea and the list? Thank us later in the comments section. Now onto the list.

The article has a list of drug patents from 2023 to 2025. If you want to get the drug patents expiration list from 2021 to 2025, Download the PDF by filling out the form below.


Patents Expiring in 2023

Entresto
Sacubitril; Valsartan

Sales:
$1.7 Billion (2018)

More information about this Drug

Patents Expiration Date
US7468390 November 27, 2023
US8101659 July 14, 2023
US8404744 July 14, 2023
US8796331 July 14, 2023

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corporation
Ingredients: Sacubitril; Valsartan
Treatment: Chronic Heart Failure

Spinraja
Nusinersen Sodium

Sales:
$1.724 Billion (2018)

More information about this Drug

Patents Expiration Date
US7101993 September 05, 2023
US8110560 December 05, 2025

Dosage: Solution; Intrathecal
Company: Biogen Idec Inc
Ingredients: Nusinersen Sodium
Treatment: Spinal Muscular Atrophy

Tegsedi
Inotersen Sodium

Sales:
$2.2 Million (Q4, 2018)

More information about this Drug

Patents Expiration Date
US7015315 March 21, 2023
US7101993 September 05, 2023

Dosage: Solution; Subcutaneous
Company: Akcea Therapeutics Inc
Ingredients: Inotersen Sodium
Treatment: Polyneuropathy

Dalvance
Dalbavancin Hydrochloride

Sales:
$81.9 Million (2019)

More information about this Drug

Patents Expiration Date
US6900175 December 25, 2023
US7115564 November 14, 2023
US7119061 November 14, 2023
US8143212 November 14, 2023

Dosage: Powder; Intravenous
Company: Allergan Sales LLC
Ingredients: Dalbavancin Hydrochloride
Treatment: To Treat Severe Skin Infections

Zykadia
Ceritinib

Sales:
$91 Million (2016)

More information about this Drug

Patents Expiration Date
US8188276 January 31, 2023
US8835430 January 31, 2023
US9018204 January 31, 2023

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Ceritinib
Treatment: Lung Cancer

Promacta
Eltrombopag Olamine

Sales:
$330 Million (Q4, 2018)

More information about this Drug

Patents Expiration Date
US7160870 May 20, 2023

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Eltrombopag Olamine
Treatment: Thrombocytopenia

Rubraca
Rucaparib Camsylate

Sales:
$142 – $143 Million (2019)

More information about this Drug

Patents Expiration Date
US6495541 November 22, 2023

Dosage: Tablet; Oral
Company: Clovis Oncology Inc
Ingredients: Rucaparib Camsylate
Treatment: BRCA-Mutated Ovarian Cancer

Mektovi
Binimetinib

Sales:
$35.1 Million (Q3, 2019)

More information about this Drug

Patents Expiration Date
US7777050 March 13, 2023
US8178693 March 13, 2023
US8193229 March 13, 2023
US8513293 March 13, 2023

Dosage: Tablet; Oral
Company: Array Biopharma Inc
Ingredients: Binimetinib
Treatment: Unresectable or Metastatic Melanoma with a BRAF V600 Mutation

Zosyn
Piperacillin Sodium, Tazobactam Sodium

Sales:
$51 Million (2019)

More information about this Drug

Patents Expiration Date
US6900184 April 14, 2023
US7915229 April 14, 2023
US8133883 April 14, 2023

Dosage: Injectable; Injection
Company: Wyeth Pharmaceuticals LLC
Ingredients: Piperacillin Sodium; Tazobactum Sodium
Treatment: Bacterial Infections

Boniva
Ibandronate Sodium

Sales:
$517 Million (2011)

More information about this Drug

Patents Expiration Date
US7192938 May 06, 2023
US7410957 May 06, 2023
US7718634 May 06, 2023

Dosage: Injectable; Injection
Company: Hoffmann La Roche Inc
Ingredients: Ibandronate Sodium
Treatment: Osteoporosis

Votrient
Pazopanib Hydrochloride

Sales:
$828 Million (2018)

More information about this Drug

Patents Expiration Date
US7105530 October 19, 2023

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Pazopanib Hydrochloride
Treatment: Soft Tissue Sarcomas and Advanced Renal Cell Carcinoma

Tyzeka
Telbivudine

Sales:

More information about this Drug

Patents Expiration Date
US7858594 September 11, 2023

Dosage: Solution; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Telbivudine
Treatment: Chronic Hepatitis B

Exforge
Amlodipine Besylate; Hydrochlorothiazide; Valsartan

Sales:
$1.025 Billion (2019)

More information about this Drug

Patents Expiration Date
US8101599 May 16, 2023
US8475839 May 16, 2023

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Amlodipine Besylate; Hydrochlorothiazide; Valsartan
Treatment: High Blood Pressure (Hypertension)

Ozurdex
Dexamethasone

Sales:
$33.7 Million (Q3, 2019)

More information about this Drug

Patents Expiration Date
US8034366 January 09, 2023
US8034370 January 09, 2023
US9192511 January 09, 2023
US10076526 January 09, 2023
US6899717 November 01, 2023
US8506987 January 09, 2023
US10702539 January 09, 2023

Dosage: Implant; Intravitreal
Company: Allergan Inc
Ingredients: Dexamethasone
Treatment: Macular Edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)

Feraheme
Ferumoxytol

Sales:
$41.7 Million (Q4, 2019)

More information about this Drug

Patents Expiration Date
US6599498 June 30, 2023

Dosage: Solution; Intravenous
Company: Amag Pharmaceuticals Inc
Ingredients: Ferumoxytol
Treatment: Iron Deficiency Anemia

Patanase
Olopatadine Hydrochloride

Sales:

More information about this Drug

Patents Expiration Date
US7977376 February 02, 2023
US8399508 September 17, 2022

Dosage: Spray, Metered; Nasal
Company: Novartis Pharmaceuticals Corp
Ingredients: Olopatadine Hydrochloride
Treatment: Congestion, Sneezing, and Runny Nose caused by Seasonal Allergies

Mozobil
Plerixafor

Sales:
$108.3 Million (2018)

More information about this Drug

Patents Expiration Date
US6987102 July 22, 2023
US7897590 July 22, 2023

Dosage: Solution; Subcutaneous
Company: Genzyme Corp
Ingredients: Plerixafor
Treatment: Non-Hodgkin’s Lymphoma or Multiple Myeloma

Section

Oraverse
Phentolamine Mesylate

Sales:

More information about this Drug

Patents Expiration Date
US7229630 June 20, 2023
US7569230 October 17, 2023

Dosage: Injectable; Injection
Company: Septodont Holding SAS
Ingredients: Phentolamine Mesylate
Treatment: Used for Reversal of the Soft-Tissue Anesthesia

Ryzolt
Tramadol Hydrochloride

Sales:

More information about this Drug

Patents Expiration Date
US7988998 October 27, 2023

Dosage: Tablet, Extended Release; Oral
Company: Purdue Pharma Products LP
Ingredients: Tramadol Hydrochloride
Treatment: Severe Pain

Patents Expiring in 2024

Mulpleta
Lusutrombopag

Sales:
200 Million Yen (2018)

More information about this Drug

Patents Expiration Date
US7601746 September 05, 2024

Dosage: Tablet; Oral
Company: Shinogi Inc
Ingredients: Lusutrombopag
Treatment: Thrombocytopenia

Invokamet XR
Canagliflozin; Metformin Hydrochloride

Sales:
$1.41 Billion (2016)

More information about this Drug

Patents Expiration Date
US8785403 July 30, 2024
US8222219 March 11, 2025

Dosage: Tablet, Extended Release; Oral
Company: Janssen Pharmaceuticals Inc
Ingredients: Canagliflozin; Metformin Hydrochloride
Treatment: Type 2 Diabetes Mellitus

Revlimid
Lenalidomide

Sales:
$10.82 Billion (2019)

More information about this Drug

Patents Expiration Date
US7855217 November 24, 2024
US7968569 October 07, 2023

Dosage: Capsule; Oral
Company: Celgene Corp
Ingredients: Lenalidomide
Treatment: Multiple Myeloma and Myelodysplastic Syndromes

Rydapt
Midostaurin

Sales:
$150 Million (2018)

More information about this Drug

Patents Expiration Date
US7973031 October 17, 2024
US8222244 October 29, 2022

Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Midostaurin
Treatment: Acute Myeloid Leukemia

Prevymis
Letermovir

Sales:
$370 Million (2020)

More information about this Drug

Patents Expiration Date
US7196086 May 22, 2024
US8513255 May 22, 2024

Dosage: Solution; Intravenous
Company: Merck Sharp And Dohme Corp
Ingredients: Letermovir
Treatment: Cytomegalovirus (CMV) infection

Vyndaqel
Tafamidis Meglumine

Sales:
$259 Million (Jan-Sep 2019)

More information about this Drug

Patents Expiration Date
US7214695 April 27, 2024
US7214696 December 19, 2023
US8168663 December 19, 2023
US8653119 January 28, 2024

Dosage: Capsule; Oral
Company: Foldrx Pharmaceuticals Inc Sub Pfizer Inc
Ingredients: Tafamidis Meglumine
Treatment: Transthyretin Amyloid Polyneuropathy

Lynparza
Olaparib

Sales:
$847 Million (2018)

More information about this Drug

Patents Expiration Date
US7151102 April 29, 2022
US7449464 October 11, 2024
US7981889 October 11, 2024
US8912187 March 12, 2024

Dosage: Capsule; Oral
Company: AstraZeneca Pharmaceuticals LP
Ingredients: Olaparib
Treatment: Advanced Ovarian Cancer, Fallopian Tube Cancer

Tasigna
Nilotinib Hydrochloride

Sales:
$1.88 Billion (2019)

More information about this Drug

Patents Expiration Date
US7169791 January 04, 2024

Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Nilotinib Hydrochloride
Treatment: Chronic Myelogenous Leukemia

Xopenex HFA
Levalbuterol Tartrate

Sales:
$148 Million (2012)

More information about this Drug

Patents Expiration Date
US7256310 October 08, 2024

Dosage: Aerosol, Metered; Inhalation
Company: Sunovion Pharmaceuticals Inc
Ingredients: Levalbuterol Tartrate
Treatment: Bronchospasm

Vandazole
Metronidazole

Sales:

More information about this Drug

Patents Expiration Date
US7456207 September 22, 2024

Dosage: Gel; Vaginal
Company: Teva Pharmaceuticals USA
Ingredients: Metronidazole
Treatment: Bacterial Vaginosis

Prialt
Ziconotide Acetate

Sales:
$27 Million (2017)

More information about this Drug

Patents Expiration Date
US8653033 October 10, 2024
US8765680 October 10, 2024
US9707270 October 10, 2024

Dosage: Injectable; Intrathecal
Company: TerSera Therapeutics LLC
Ingredients: Ziconotide Acetate
Treatment: Pain Reliever

Aloxi
Palonosetron Hydrochloride

Sales:
$400 Million (2019)

More information about this Drug

Patents Expiration Date
US7947724 January 30, 2024
US7947725 January 30, 2024
US7960424 January 30, 2024
US8518981 January 30, 2024
US8598218 January 30, 2024
US9173942 January 30, 2024
US9439854 January 30, 2024
US9457020 January 30, 2024

Dosage: Injectable; Intravenous
Company: Helsinn Healthcare SA
Ingredients: Palonosetron Hydrochloride
Treatment: Acute Nausea and Vomiting

Patents Expiring in 2025

Xalkori
Crizotinib

Sales:
$524 Million (2018)

More information about this Drug

Patents Expiration Date
US7230098 August 26, 2025
US8785632 March 01, 2025

Dosage: Capsule; Oral
Company: Pfizer
Ingredients: Crizotinib
Treatment: Non-Small Cell Lung Carcinoma

Omegaven
Fish Oil Triglycerides

Sales:

More information about this Drug

Patents Expiration Date
US9566260 July 11, 2025
US9629821 July 11, 2025
US10350186 November 05, 2024

Dosage: Emulsion; Intravenous
Company: Fresenius Kabi USA LLC
Ingredients: Fish Oil Triglycerides
Treatment: Parenteral Nutrition-Associated Cholestasis (PNAC)

Yupelri
Revefenacin

Sales:
$3.3 Million (Q4, 2018)

More information about this Drug

Patents Expiration Date
US7288657 December 23, 2025
US7491736 March 10, 2025
US7521041 March 10, 2025
US7550595 March 10, 2025
US7585879 March 10, 2025

Dosage: Solution; Inhalation
Company: Mylan Ireland Ltd
Ingredients: Revefenacin
Treatment: Chronic Obstructive Pulmonary Disease

Sprycel
Dasatinib

Sales:
$2 Billion (2018)

More information about this Drug

Patents Expiration Date
US8680103 February 04, 2025

Dosage: Tablet; Oral
Company: Bristol Myers Squibb Co
Ingredients: Dasatinib
Treatment: Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL)

Bosulif
Bosutinib Monohydrate

Sales:
$477 Million (2019)

More information about this Drug

Patents Expiration Date
US7417148 December 11, 2025
US7767678 November 23, 2026
US7919625 December 11, 2025

Dosage: Tablet; Oral
Company: PF Prism CV
Ingredients: Bosutinib Monohydrate
Treatment: Chronic Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

Cresemba
Isavuconazonium Sulfate

Sales:
$180 Million (Jul 2018 – Jun 2019)

More information about this Drug

Patents Expiration Date
US6812238 October 31, 2025

Dosage: Capsule; Oral
Company: Astellas Pharma US Inc
Ingredients: Isavuconazonium Sulfate
Treatment: Invasive Aspergillosis And Mucormycosis

Antara
Fenofibrate

Sales:
$70 Million (2008)

More information about this Drug

Patents Expiration Date
US8026281 April 22, 2025

Dosage: Capsule; Oral
Company: Lupin Inc
Ingredients: Fenofibrate
Treatment: High Cholesterol and Triglycerides (fatty acids) in Blood

Section

Lysteda
Tranexamic Acid

Sales:
$25 Million (2012)

More information about this Drug

Patents Expiration Date
US7947739 March 04, 2025
US8022106 March 04, 2025
US8273795 March 04, 2025
US8487005 March 04, 2025
US8791160 March 04, 2025
US8809394 March 04, 2025
US8957113 March 04, 2025
US9060939 March 04, 2025

Dosage: Tablet; Oral
Company: Amring Pharmaceuticals Inc
Ingredients: Tranexamic Acid
Treatment: Cyclic Heavy Menstrual Bleeding

Bepreve
Bepotastine Besilate

Sales:
$160.3 Million (2011)

More information about this Drug

Patents Expiration Date
US8784789 January 13, 2025
US8877168 July 30, 2023

Dosage: Solution/Drops; Ophthalmic
Company: Bausch And Lomb Inc
Ingredients: Bepotastine Besilate
Treatment: Itching of the Eyes due to Allergies

Sancuso
Granisetron

Sales:
$20 – $25 Million

More information about this Drug

Patents Expiration Date
US7608282 January 22, 2025

Dosage: Film, Extended Release; Transdermal
Company: Kyowa Kirin Inc
Ingredients: Granisetron
Treatment: Nausea and Vomiting Caused by Cancer Chemotherapy

Nucynta
Tapentadol Hydrochloride

Sales:
$46.8 Million (2019)

More information about this Drug

Patents Expiration Date
US7994364 June 27, 2025

Dosage: Tablet; Oral
Company: Collegium Pharmaceuticals Inc
Ingredients: Tapentadol Hydrochloride
Treatment: Moderate to Severe Pain

Nexlizet
Bempedoic Acid, Ezetimibe

Sales:

More information about this Drug

Patents Expiration Date
US7335799 December 03, 2025

Dosage: Tablet; Oral
Company: Esperion Therapeutics Inc
Ingredients: Bempedoic Acid, Ezetimibe
Treatment: Reduce the Amount of Cholesterol and other Fatty Substances in Blood

Conclusion

As a drug patent expires it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version. 

With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it? Well, let’s start with getting in touch by filling the form below and we’ll get back to you in no time.


Authored by: Divya Goyal, Team Lead, Life Science Team, and Madan Ekhande, Research Analyst, Life Science Team

Leave a Comment

Contact Us

Got Questions! Queries! Send us an email.